Janusz Bednarski

TL;DR: The prescription of VKAs declined significantly after the introduction of NOACs, and patients with persistent and permanent AF were more likely to receive rivaroxaban, in comparison to patients on VKAs and dabigatran.

TL;DR: Despite a high stroke risk as determined by both scores, only 39% of patients received OAC, and those prescribed OAC treatment were younger, more often male, with permanent AF, valvular heart disease, and hypertension.

TL;DR: In HF patients treated with torasemide fluid overload and symptoms improved more than in the furosemide group, this positive effect occurred already within 3-month observation.

TL;DR: Patients with AF and CHF had a higher thromboembolic risk and had more concomitant diseases, including chronic kidney disease and chronic obstructive pulmonary disease.

TL;DR: Patients with AF treated with OACs in the district and academic hospitals have different clinical characteristics, with older, had more comorbidities, more frequently had permanent AF, and were at higher risk of thromboembolic and bleeding events than patients treated in the academic hospital.